Wednesday, October 7, 2015
Teva Pharmaceutical Industries has agreed to acquire Representaciones e Investigaciones Médicas (Rimsa), a pharmaceutical manufacturing and distribution company in Mexico, along with a portfolio of products and companies, intellectual property, assets and pharmaceutical patents in Latin America and Europe in a debt-free, cash free set of transactions, for an aggregate of $2.3 billion.
C.R. Bard, a Murray Hill, N.J.-based multinational developer, manufacturer and marketer of medical technologies, has entered into a definitive agreement to acquire Kobayashi Pharmaceutical’s 50% ownership share in Medicon—the Osaka, Japan-based venture that the two companies have operated together since 1972—through a share redemption. The transaction is expected to close in early November, after which Medicon will be a wholly owned subsidiary of the company. The transaction has been approved by each company’s board of directors and is subject to customary closing conditions.
Martindale Pharma, a U.K.-based international specialty pharmaceutical company, has opened a scientific office in the Kingdom of Saudi Arabia (KSA) and has appointed Dr. Fahad Al Showaier as scientific office manager. He brings extensive international experience, having previously held a number of senior positions with Saudi companies including Jamjoom Pharma.
Cloud Pharmaceuticals, a cloud-based drug design and development company located in Research Triangle Park, N.C., and Switzerland-based THERAMetrics have formed a strategic collaboration focusing on the design and development of therapeutics for orphan central nervous system (CNS) diseases and other indications.
Teva Pharmaceutical Industries, based in Israel, has agreed to acquire Cambridge, Mass.-based Gecko Health Innovations, a privately held company focused on developing software and product solutions to aid in compliance and adherence improvement in the management of respiratory disease.
Intarcia Therapeutics has announced the acquisition of Phoundry Pharmaceuticals, a privately held biotechnology company based in Research Triangle Park, N.C. Founded in 2015 after six years of work as part of the Enteroendocrine Discovery Performance Unit of GlaxoSmithKline, Phoundry Pharmaceuticals has created a portfolio of optimized peptides in various therapeutic categories, most notably diabetes and obesity.
Novartis has launched Novartis Access, a portfolio of 15 medicines to treat chronic diseases in low- and low-middle-income countries. The portfolio addresses cardiovascular diseases, diabetes, respiratory illnesses and breast cancer and will be offered to governments, non-governmental organizations (NGOs) and other public-sector healthcare providers for $1 per treatment, per month.
Clinigen Group, a specialty global pharmaceutical company, has agreed to acquire Link Healthcare, a specialist pharmaceutical and medical technology business focused on the Asia, Africa and Australasia (AAA) region, for an initial consideration of $67.9 million and a maximum of approximately $152.5 million based on achievement of milestones.